Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6952W HIGH $1,725.00
Volume
9.79 K
Value Traded
36.68 K
Short % Float
14.97%
Days to Cover
1.0
-10.21%Week
-59.99%1 Month
-81.82%3 Month
-98.74%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
437.34 K
EPS (TTM)
-63.93
P/E Ratio
-
Ent. Value
-294.99 K
Total Shares
605.65 K
Float Shares
520.00 K
Insiders
14.34%
Institutions
0.45%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
PFSA Catalyst Timeline
Dated clinical, regulatory and corporate events for Profusa, Inc.
Past FDA Catalysts and PDUFA Decisions
How PFSA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Profusa, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PFSA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Lumee | peripheral artery disease | 2026-01-29 | Results from 15 PAD patients with subcutaneous hydrogel sensors implanted in the arm and foot. Tissue oxygenation was measured using both Lumee sensors and tcpO₂. Sensors were monitored over 12 months with visits at days 2, 10, 90, 180, and 365.Read More | Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HRT FINANCIAL LP10% Owner | Sell | -18,395 | $5.94 | 08/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PFSA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in PFSA for Q2 2026. | ||||
Ownership Trends
PFSA Short Interest
Shares sold short, counted twice a month.
14.97%
Short % of Float
of tradable shares sold short
77.8K
Shares Sold Short
-51.5% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
645.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PFSA ranks across every disease it competes in
Competitive Position is a premium feature
See how PFSA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPFSA News
-PFSA
Oct 15, 2026▼ -16.4%on this news· ran to -31% by day 3
Profusa Receives ISO 13485:2016 Certificate from GMED
Profusa, Inc. has achieved ISO 13485:2016 certification from GMED, a key milestone for its Lumee Oxygen Platform. This certification supports ongoing conformity assessment activities under the EU Medical Device Regulation (MDR) and is essential for future commercialization in Europe. While the certification enhances Profusa's credibility, the timing of MDR certification and market entry remains uncertain.
Read more →-PFSA
Sep 24, 2026▲ +47.8%on this news
Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October
Profusa, Inc. announced a positive decision from GMED for ISO 13485 certification, marking a significant milestone in its quality management system. The company is progressing towards CE marking for its Lumee Oxygen Platform, which monitors tissue oxygen levels. However, there remains uncertainty regarding the timing and outcome of the remaining assessment activities.
Read more →-PFSA
Sep 15, 2026▼ -29.3%on this news
Profusa, Inc. Receives Nasdaq Compliance Determination
Profusa, Inc. has received confirmation from Nasdaq that it complies with key listing rules. The company is under a one-year Mandatory Panel Monitor, which requires ongoing compliance to avoid delisting. Profusa is also exploring an acquisition of G3 Vision Labs to strengthen its position in the diagnostics sector.
Read more →-PFSA
Aug 31, 2026Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement
Profusa, Inc. has announced compliance with Nasdaq's publicly held shares requirement after receiving a notice regarding a deficiency. Following a reverse stock split, the company confirmed it meets the necessary criteria as of August 21, 2026. This compliance ensures that Profusa's securities will continue trading on the Nasdaq Capital Market without interruption.
Read more →-PFSA
Aug 20, 2026▼ -44.2%on this news· ran to -63% by day 3
Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company
Profusa, Inc. reported its Q2 2026 financial results, highlighting a successful reverse stock split and progress on an Option Agreement to acquire G3 Vision Labs. The company has secured sufficient working capital and expects an increase in stockholders' equity. However, it also reported significant net losses and high current liabilities, indicating ongoing financial challenges.
Read more →-PFSA
Aug 13, 2026Profusa Announces 1-for-4 Reverse Stock Split
Profusa, Inc. has announced a one-for-four reverse stock split effective August 17, 2026. This move will reduce the number of outstanding shares from approximately 2.4 million to about 605,726 shares, while maintaining the authorized share count at 601 million. The reverse split aims to consolidate shares and potentially improve market perception.
Read more →-PFSA
Jul 31, 2026▼ -9.2%on this news
Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs
Profusa, Inc. has signed an Option Agreement to acquire G3 Vision Labs, which includes its subsidiaries. The agreement allows Profusa to exercise the option under specific conditions, including financial commitments and approvals. If successful, the acquisition will enhance Profusa's capabilities in the diagnostics sector, leveraging G3's established revenue stream.
Read more →-PFSA
Jul 27, 2026▼ -28.7%on this news· ran to -39% by day 1
Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company
Profusa, Inc. has signed a non-binding term sheet to acquire a commercial-stage diagnostics company, which is expected to enhance its operational capabilities and revenue streams. The leadership has undergone significant changes, with Jack Stover appointed as Executive Chairman and CEO. The acquisition, pending due diligence, aims to create a public diagnostics company with national laboratories.
Read more →-PFSA
Jul 2, 2026▼ -23%on this news
Profusa Announces 1-for-25 Reverse Stock Split
Profusa, Inc. has announced a one-for-twenty-five reverse stock split effective July 7, 2026. This action will consolidate approximately 13.2 million shares into about 530 thousand shares, while maintaining the number of authorized shares at 601 million. The move aims to enhance the company's stock value and trading stability.
Read more →-PFSA
Jun 24, 2026▼ -9.7%on this news· ran to -20% by day 3
Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts
Profusa, Inc. announced that shareholders approved all proposals during its 2026 Annual Meeting, including the acquisition of the PanOmics diagnostics platform. The approved measures aim to strengthen the company's balance sheet and ensure compliance with Nasdaq listing requirements. CEO Ben Hwang emphasized the strategic importance of these initiatives for future growth and innovation.
Read more →-PFSA
Jun 12, 2026▼ -17.7%on this news
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
Profusa, Inc. has submitted a response package to GMED as part of the CE Mark review for its Lumee Oxygen Platform. This submission follows successful assessments of the company's quality system and technical documentation. The Lumee platform aims to provide continuous tissue oxygen monitoring, addressing significant clinical needs. However, the review process remains ongoing with uncertain outcomes.
Read more →-PFSA
Jun 10, 2026▼ -9.7%on this newsshared move
Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting
Profusa, Inc. has issued a letter encouraging shareholders to vote in favor of several key proposals at the upcoming Annual Meeting on June 23, 2026. The proposals aim to support the company's Nasdaq listing and facilitate the acquisition of the PanOmics Assay platform. The Board believes these measures are crucial for the company's growth and operational success.
Read more →-PFSA
May 15, 2026Profusa Announces Listing Transfer to The Nasdaq Capital Market
Profusa, Inc. has announced its transfer to The Nasdaq Capital Market effective May 15, 2026. This transition is part of a series of milestones set by the Nasdaq Hearings Panel to ensure compliance with listing requirements. The company focuses on developing tissue-integrated sensors for continuous health monitoring.
Read more →-PFSA
May 8, 2026▲ +5.3%on this news
Profusa Receives Favorable Nasdaq Listing Determination
Profusa, Inc. has received approval from the Nasdaq Hearings Panel to transfer its listing from The Nasdaq Global Market to The Nasdaq Capital Market. This decision is contingent upon the company's ability to meet specific interim milestones and comply with certain financial requirements by July 6, 2026. Profusa is focused on developing tissue-integrated sensors for continuous biochemical monitoring.
Read more →-PFSA
Apr 6, 2026▲ +144.1%on this news
Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform
Profusa, Inc. has announced a strategic expansion into molecular diagnostics with a $30 million Letter of Intent to acquire the PanOmics platform from BioInsights LLC. This acquisition aims to enhance Profusa's capabilities in precision diagnostics, particularly for pancreatic cancer applications, and is supported by a partnership with Mayo Clinic. The deal is expected to provide a clear pathway to commercialization and significant growth potential.
Read more →-PFSA
Feb 27, 2026▼ -14.8%on this news
Profusa To Withdraw S-1 Registration Statement to Pursue a Smaller, More Focused Offering
Profusa, Inc. has decided to withdraw its S-1 Registration Statement to pursue a smaller offering that aligns better with its operational needs. The company aims to support the projected revenue from its Lumee Oxygen product and its collaboration with the Mayo Clinic. This decision reflects confidence in their recent operational progress and future market entry plans.
Read more →-PFSA
Feb 13, 2026▼ -33.4%on this news· ran to -44% by day 3
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
Profusa has partnered with Mayo Clinic to advance the commercialization of its Lumee wearable oxygen monitoring technology. This collaboration aims to explore high-impact clinical applications, particularly in areas like cardiovascular and orthopedic health. The initiative seeks to improve patient outcomes through continuous monitoring of tissue oxygen levels, addressing unmet clinical needs.
Read more →-PFSA
Feb 5, 2026▼ -36.4%on this news· ran to -54% by day 3
Profusa Announces 1-for-75 Reverse Stock Split
Profusa, Inc. has announced a 1-for-75 reverse stock split effective February 9, 2026. This consolidation will reduce the number of outstanding shares from approximately 92.4 million to about 1.2 million, while maintaining the par value per share. The move aims to enhance the stock's market perception and streamline trading on Nasdaq.
Read more →-PFSA
Jan 29, 2026Profusa Presents Positive US-Study Clinical Results at Leipzig Interventional Course (LINC) 2026
Profusa, Inc. presented positive results from a US clinical study on its Lumee oxygen monitoring technology for peripheral artery disease (PAD) patients at the Leipzig Interventional Course 2026. The study demonstrated safety and effectiveness, showing a strong correlation with traditional monitoring methods. The company anticipates significant revenue growth from its European operations starting in Q2 2026.
Read more →-PFSA
Jan 16, 2026Profusa Launches Lumee™ Tissue Oxygen Healthcare Research Offerings, Initiating First Commercial Revenue
Profusa, Inc. has launched its Lumee tissue oxygen monitoring system for contract research organizations (CROs), aiming to generate immediate revenue. This initiative targets the expanding CRO market, projected to grow significantly by 2034. The system offers real-time biological data, enhancing drug development processes and decision-making for pharmaceutical partners.
Read more →About Profusa, Inc.
Headquarters207 WEST 25TH ST, 9TH FLOOR, NEW YORK, NY, 10001
BIOPHARMAWATCH ELITE PLUS
Trade the next PFSA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime